An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Severe Atopic Dermatitis
ABOUT THE GALDERMA CLINICAL STUDY IN ATOPIC DERMATITIS
Galderma is conducting a clinical study in patients with atopic dermatitis (AD), also called eczema. The objective of this clinical study is to determine if there are pharmacologic interactions between some commonly used medications and an investigational medication called nemolizumab in patients with moderate-to-severe AD (this type of study is called a drug interaction study).
Nemolizumab is currently being developed by Galderma as a potential treatment for AD.
The Galderma drug interaction study (EUDRA CT 2020-000229-24) has been reviewed and authorized by the FDA.
For more information, please take a look at our Additional Information section below or visit https://www.galderma.com/us/bringing-innovation-life.
Atopic dermatitis (AD) is a chronic inflammatory skin disease estimated to occur in 10% to 20% of the adult population. The disease is characterized by itching (also called pruritus), skin dryness and skin lesions whose features include redness, oozing with crusting, scratches or abrasions, and areas of the skin that become thickened and hardened. The scratching behavior associated with the itching is believed to worsen the AD lesions by causing mechanical damage to the skin allowing the penetration of bacteria which triggers inflammatory responses, leading to further worsening of the itching and inflammation of the skin.
